TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04230863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuroplasticity-based Computerized Cognitive Remediation
Description: The nCCR has two major components: Bottom up and Top down training. Bottom up training: The training includes selected tasks from Brain HQ, a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.~Top down training: We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These Top Down Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization.
Study: NCT00413959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE®
Description: 1.6 mg/m\^2 of Velcade® given intravenously on days 1, 8, 15 and 22.
Study: NCT04165148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Impact Laparoscopy
Description: Low Impact Laparoscopy is a minimally invasive technique that combines low pressure insufflation (with the iFS AirSeal® system) and microcoelioscopy (with specific microtrocards and laparoscopic instruments).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional laparoscopy
Description: conventional laparoscopy
Study: NCT00413959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 of Rituximab given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 400 mg/m\^2 of Cyclophosphamide given orally on days 1-4 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decadron
Description: 40 mg given orally on days 1, 2, 8, 9, 15, 16, 22 and 23
Study: NCT02288273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bydureon
Description: Once weekly injection of 2mg bydureon (extended release exenatide) for 10 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04165148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS) for Pain
Description: The patient evaluates her pain using an VAS scale on arrival in the post-interventional surveillance room, then 30 minutes, 2 hours, 4 hours, 6 hours after leaving the operating roo, at the exit of post-interventional surveillance room and at the exit of the hospital.~The day after surgery, according to the usual practice, outpatients receive a telephone call from a Gynecologist. The assessment of their pain (with VAS scale) will be collected.~During the usual consultation at 1 month, the patient must evaluate her pain by means of an VAS.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual Analog Scale (VAS) for Pain
Description: The patient evaluates her pain using an VAS scale on arrival in the post-interventional surveillance room, then 30 minutes, 2 hours, 4 hours, 6 hours after leaving the operating roo, at the exit of post-interventional surveillance room and at the exit of the hospital.~The day after surgery, according to the usual practice, outpatients receive a telephone call from a Gynecologist. The assessment of their pain (with VAS scale) will be collected.~During the usual consultation at 1 month, the patient must evaluate her pain by means of an VAS.
Study: NCT03913156

Intervention type: OTHER
Group type: OTHER
Intervention: B2970 Metabolic Texture Modified Protein Substitute
Description: The study product is a powdered phe-free protein substitute supplemented with long chain polyunsaturated fatty acids (LCP's), containing essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals and trace elements and has been designed for use in the management of proven PKU in children aged 6 months to 5 years.
Study: NCT04055428

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Meals
Description: Participants will consume the standardized study mixed meal for the assessment of postprandial GLP-1 response to the meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise capacity VO2 maximum determination
Description: Each participant's maximal oxygen capacity will be determined using modified Bruce treadmill protocol.
Study: NCT01997463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supervised asthma therapy in schools
Description: Therapy observed daily in school. Asthma education by American Lung Association
Study: NCT03598387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated peritoneal dialysis
Description: The prescription of automated peritoneal dialysis:~* The first 48-72 hours dose: 0.8-2.0 liter exchange with 1-2 hour-cycle (8-36 liters per day); After initial 48-72 hours, 1.0-2.5L exchange with 2-6 hour-cycle (at least 8 liters per day), if the acidosis, hyperkalemia and pulmonary edema are corrected.~* The minimal target weekly Kt/V is 2.1-3.5/W.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent hemodialysis
Description: Intermittent hemodialysis will be performed 3-4h of each session and 2-5 times per week. The prescription will be adjusted based on patients' conditions to ensure spKT/V≥1.3.
Study: NCT01230879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EFR and TDM
Description: EFR : Pulmonary function test TDM : tomodensitometry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EFR and TDM
Description: EFR : Pulmonary function test TDM : tomodensitometry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EFR and TDM
Description: EFR : Pulmonary function test TDM : tomodensitometry
Study: NCT02109341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel bound albumine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel bound albumine
Study: NCT00630331

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell culture-derived influenza vaccine
Description: One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Egg-derived influenza virus vaccine
Description: One dose (0.5 mL) of the trivalent egg-derived influenza virus vaccine, administered in the deltoid muscle.
Study: NCT04055428

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise capacity VO2 maximum determination
Description: Each participant's maximal oxygen capacity will be determined using modified Bruce treadmill protocol.
Study: NCT03104660

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CE certified mitral valve repair systems
Description: Patients receive a transcatheter mitral valve repair with CE certified transcatheter mitral repair systems.
Study: NCT01785173

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic-guided gauze pledgetting
Description: By using a transnasal endoscope as a guide and a biopsy forceps, a gauze strip soaked with decongestant and anesthesia will be delivered to a selected nasal meatus chosen by anterior rhinoscopy.
Study: NCT04165148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saint-Antoine Pain Questionnaire (QDSA)
Description: The patient evaluates her pain using an QDSA questionnaire on arrival in the post-interventional surveillance room, then 30 minutes, 2 hours, 4 hours, 6 hours after leaving the operating roo, at the exit of post-interventional surveillance room and at the exit of the hospital.~The day after surgery, according to the usual practice, outpatients receive a telephone call from a Gynecologist. The assessment of their pain (with QDSA questionnaire) will be collected.~During the usual consultation at 1 month, the patient must evaluate her pain by means of an QDSA questionnaire.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saint-Antoine Pain Questionnaire (QDSA)
Description: The patient evaluates her pain using an QDSA questionnaire on arrival in the post-interventional surveillance room, then 30 minutes, 2 hours, 4 hours, 6 hours after leaving the operating roo, at the exit of post-interventional surveillance room and at the exit of the hospital.~The day after surgery, according to the usual practice, outpatients receive a telephone call from a Gynecologist. The assessment of their pain (with QDSA questionnaire) will be collected.~During the usual consultation at 1 month, the patient must evaluate her pain by means of an QDSA questionnaire.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: post-operative questionnaire
Description: The patient will fill in the antalgic intake record and the patient booklet for the collection of medical consumptions from her discharge from the hospital and during the month following the surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: post-operative questionnaire
Description: The patient will fill in the antalgic intake record and the patient booklet for the collection of medical consumptions from her discharge from the hospital and during the month following the surgery.
Study: NCT02700464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bladder EpiCheck Urine Test
Description: The Bladder EpiCheck test is an in vitro diagnostic device for the detection of DNA methylation patterns in urine that are associated with bladder cancer. It is intended for use as a noninvasive method for monitoring for tumor recurrence in conjunction with cystoscopy inpatients previously diagnosed with bladder cancer
Study: NCT00630331

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose (0.5 mL) of phosphate buffered solution.
Study: NCT02402855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delivery of a prepaid payment card
Description: Delivery of a prepaid payment card credited according to consultations attended

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview with a sociologist
Description: For a sub-group of 40 womens

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Study: NCT04173819

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS-J
Description: 300mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3BNC117-LS-J
Description: 300mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10-1074-LS-J
Description: 300mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10-1074-LS-J
Description: 300mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combination 3BNC117-LS-J and 10-1074-LS-J
Description: 30mg/kg of each

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1
Description: Total \~300 mg (\< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2
Description: Total \~300 mg (\< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2
Description: Total \~300 mg (\< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2
Description: Total \~300 mg (\< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3
Description: Total \~300 mg (\< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Saline

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Saline

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Saline

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Buffer Solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Buffer Solution
Study: NCT01785173

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cotton-tipped applicator gauze pledgetting
Description: In contrast to the endoscopic-guided, forceps-delivering method, a gauze strip is delivered to a selected meatus by a cotton-tipped applicator.
Study: NCT00561860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine Arm
Description: Telemedicine involves the provision or support of direct clinical care via the application of electronic and communicating technology, including the remote monitoring of health status. By providing patient data early in the course of CPAP prescription, we believe that this technology would be immensely useful in improving compliance and acceptance of the device in patients with sleep apnea.
Study: NCT04619160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: TCI 4 µg/mL start until BIS-value of 50

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: start 1 MAC, until BIS-value of 50
Study: NCT02490020

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell
Study: NCT00095940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT04173819

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Buffer Solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Buffer Solution
Study: NCT00095940

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Correlative studies
Study: NCT04173819

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Buffer Solution
Study: NCT02700464

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cystoscopy and pathology
Description: Routine cystoscopy for bladder cancer recurrence and pathology confirmation for patients with positive cystoscopy
Study: NCT00711464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil (M1, M2, M4)
Description: modafinil 100, 200, and 400 mg oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil (M1, M2, M4)
Description: modafinil 100, 200, and 400 mg oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: modafinil (M1, M2, M4)
Description: modafinil 100, 200, and 400 mg oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: modafinil (M1, M2, M4)
Description: modafinil 100, 200, and 400 mg oral dose
Study: NCT00983684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrabeam
Description: A dose of 20 Gy at the surface of the applicator or 6 Gy at 1cm (in water) is prescribed by the radiation oncologist and delivered to the breast tissue. This takes approximately 30 minutes, depending on the size of the applicator.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Post-operative radiotherapy
Description: All patients randomised to receive conventional radiotherapy within this trial should be treated in accordance with a pre-specified policy. Dosage should only be applied to the breast; axillary, supra-clavicular and internal mammary nodes should not generally be irradiated by discrete fields.
Study: NCT03192696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atherectomy Catheter
Description: Treatment of restenotic lesions within stents previously placed within the artery.
Study: NCT00539266

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bone marrow derived mononuclear cells
Description: 40 IM injections (calf muscle) of 1-8 10E9 mono nuclear cells

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bone marrow derived mononuclear cells
Description: 40 IM injections (calf muscle) of 1-8 10E9 mono nuclear cells

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 40 IM injections (calf muscle) of placebo suspension

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 40 IM injections (calf muscle) of placebo suspension
Study: NCT02464709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid
Description: A 0,25mm-thick layer of BF-200 ALA (aminolevulinic acid, Ameluz®) light sensitizer gel is applied on one randomized treatment side of face.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyl 5-aminolevulinate
Description: A 0,25mm-thick layer of MAL (methyl 5-aminolevulinate, Metvix®) light sensitizer cream is applied on one randomized treatment side of face.
Study: NCT03202576

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Bridle
Description: Nasal bridle placement and securement of the tube. Instead of taping the tube to the patient's face, nose or upper lip the bridle is a device whereby a magnetic retrieval system is attached to 1/8 inch umbilical tape which is inserted via the nares, looping around the nasal septum and vomer bone and ending with both ends of the bridle (umbilical tape) secured together and to the feeding tube just outside the nose.
Study: NCT01376102

Intervention type: DRUG
Intervention: BONVIVA(ibandronate) injection
Description: Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
Study: NCT03575715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EBUS
Description: EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
Study: NCT00804115

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Latanoprost with Pilocarpine vs Timolol or Cosopt
Description: Timolol 0.5% bid or Cosopt bid Latanoprost 0.005% qhs Pilocarpine 2%

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Latanoprost with Pilocarpine vs Timolol or Cosopt
Description: Timolol 0.5% bid or Cosopt bid Latanoprost 0.005% qhs Pilocarpine 2%
Study: NCT00821678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine Outreach for PTSD
Description: The intervention involves an off-site PTSD care team (tele-psychiatrist, tele-psychologist, tele-pharmacist, and tele-nurse care manager) and uses telemedicine technologies (telephone, interactive video and electronically shared medical records). A dedicated nurse telephone care manager educates/activates patients, identifies preferences, overcomes treatment barriers, monitors symptoms, side-effects and adherence, identifies psychiatric comorbidities, and encourages patient self-management. Tele-pharmacists provide medication management by phone. Tele-psychologists provide Cognitive Processing Therapy via interactive video. Tele-psychiatrists supervise the off-site care team as well as conduct consultations and provide medication management via interactive video.
Study: NCT03222466

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Co-created PEM
Description: A co-created PEM has been designed in collaboration with patients.
Study: NCT03006861

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3.5 mL/d topical creatine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 3.5 mL/d topical creatine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3.5 mL/d topical placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 3.5 mL/d topical placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 21 g/d Oral creatine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 21 g/d oral placebo
Study: NCT01386333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin
Description: Patients will be randomized to receive intranasal oxytocin or placebo in a dose escalation paradigm with three dose cohorts: 24IU, 48IU and 72IU of intranasal oxytocin twice daily for 1 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin
Description: Patients will be randomized to receive intranasal oxytocin or placebo in a dose escalation paradigm with three dose cohorts: 24IU, 48IU and 72IU of intranasal oxytocin twice daily for 1 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin
Description: Patients will be randomized to receive intranasal oxytocin or placebo in a dose escalation paradigm with three dose cohorts: 24IU, 48IU and 72IU of intranasal oxytocin twice daily for 1 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxytocin
Description: Patients will be randomized to receive intranasal oxytocin or placebo in a dose escalation paradigm with three dose cohorts: 24IU, 48IU and 72IU of intranasal oxytocin twice daily for 1 week
Study: NCT01221935

Intervention type: OTHER
Intervention: Pristiq first-line treatment charts
Description: 300 charts including patients initiated on Pristiq within the past 6 months as a first-line treatment

Intervention type: OTHER
Intervention: Pristiq second-line treatment charts
Description: 800 charts including patients initiated on Pristiq within the past 6 months as a second-line treatment (following first-line treatment with a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)).
Study: NCT01386333

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Nasal Mist
Description: Placebo arm wil receive saline nasal mist sprays matched in number to oxytocin dose cohorts